QIPT trades 0.0% below Wall Street's consensus target of $3.65.
Last 12 months price action with 12-month analyst target path
The base valuation assumes QIPT achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Quipt Home Medical Corp. (QIPT) has a Wall Street consensus price target of $3.65, based on estimates from 2 covering analysts. With the stock currently trading at $3.65, this represents a potential upside of +0.0%. The company has a market capitalization of $161M.
Analyst price targets range from a low of $3.65 to a high of $3.65, representing a 0% spread in expectations. The median target of $3.65 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, QIPT trades at a trailing P/E of -14.6x. Analysts expect EPS to grow -82.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
HCSGHealthcare Services Group, Inc. | $1.6B | $22.54 | $24.50 | +6.8% | Hold | 21.2x | 15 |
EHABEnhabit, Inc. | $707M | $13.80 | $13.53 | -2.0% | Hold | 23.0x | 11 |
NKTRNektar Therapeutics | $1.3B | $65.70 | $149.60 | +145.3% | Buy | — | 33 |
INVAInnoviva, Inc. | $1.7B | $22.67 | $37.00 | +64.5% | Buy | 6.3x | 10 |
LINCLincoln Educational Services Corporation | $1.6B | $49.33 | $53.80 | +11.1% | Buy | 61.6x | 15 |
SUPNSupernus Pharmaceuticals, Inc. | $2.6B | $44.48 | $60.00 | +35.2% | Buy | 17.8x | 14 |
PHGKoninklijke Philips N.V. | $25.7B | $26.98 | — | — | Hold | 17.1x | 22 |
AVNSAvanos Medical, Inc. | $1.2B | $24.90 | $23.00 | -7.8% | Hold | 24.9x | 8 |
HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
MASIMasimo Corporation | $9.4B | $179.95 | $180.00 | +0.0% | Buy | 32.7x | 23 |
Quick answers to the most common questions about buying QIPT stock.
The consensus price target for QIPT is $3.65, close to the current price of $3.65 (0.0% implied move). Based on 2 analyst estimates, the stock appears fairly valued near current levels.
QIPT has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is mixed, with 1 Hold ratings making up the largest segment. The consensus 12-month price target of $3.65 implies 0.0% upside from current levels.
QIPT's current price is $3.65 with a consensus target of $3.65 (0.0% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $3.65 for QIPT, while the most conservative target is $3.65. The consensus of $3.65 represents the median expectation. These targets typically reflect 12-month expectations.
QIPT is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month QIPT stock forecast based on 2 Wall Street analysts shows a consensus price target of $3.65, with estimates ranging from $3.65 (bear case) to $3.65 (bull case). The median consensus rating is "Buy".
QIPT appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $3.65 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
QIPT analyst price targets range from $3.65 to $3.65, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $3.65 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.